Genitourinary Cancers | Specialty

Dr. Motzer Analyzes Overall Survival in the TIVO-1 Study

February 15th 2013

Robert J. Motzer, MD, from Memorial Sloan-Kettering Cancer Center, discusses the overall survival results from the phase III TIVO-1 study that compared tivozanib to sorafenib in patients with renal cell carcinoma.

Dr. Deepak Kapoor on the Utilization of Prostate Biopsies

February 14th 2013

Deepak A. Kapoor, MD, president of the Large Urology Group Practice Association, discusses the implications of a large study looking at the detection of prostate cancer using prostate biopsies.

A United Front: Chesapeake Urology Associates Puts Its Singular Spin on Integrative Care

January 17th 2013

When the founding partners of Chesapeake Urology Associates (CUA) in Maryland decided to merge their practices, Sanford J. Siegel, MD, CUA's president and CEO, drew inspiration from another consolidation process.

Multidisciplinary Prostate Cancer Care at Duke Cancer Institute: An Interview With Judd W. Moul, MD

January 16th 2013

Judd W. Moul, MD, from the Duke Cancer Institute, comments on practice trends in urologic cancer care and the advantages and disadvantages of his institution's multidisciplinary prostate cancer clinic.

Dr. Sridhar on Nab-Paclitaxel in Urothelial Cancer

January 10th 2013

Srikala Sridhar, MD, MSc, from the University of Toronto, Canada, discusses the results of a single arm phase II trial examining nab-paclitaxel as a secondary treatment for urothelial cancer.

Nab-Paclitaxel Continues to Be Explored in Advanced Urothelial Cancer

January 3rd 2013

Nab-paclitaxel might offer some hope for patients with advanced urothelial cancer, an area that has lagged behind the rapid growth in available therapies for other genitourinary cancers.

The Challenges That Lie Ahead

December 13th 2012

As many of us are keenly aware, the coming 12 months present some very challenging times in the medical community.

The USPSTF Prostate Cancer Screening Recommendations: Urologists Discuss Its Message and Impact on Their Practices

December 12th 2012

A panel of experts provides their thoughts on the USPSTF PSA screening recommendations, and how this widely publicized health message has impacted their urology practices.

Dr. Shore on Current Clinical Trial Challenges in CRPC

December 12th 2012

Effective Management of Prostate Cancer Conclusion

December 12th 2012

Revenue Opportunities and GPOs for Urology Groups

December 12th 2012

Reimbursement Issues in Prostate Cancer, Part II

December 12th 2012

Reimbursement Issues in Prostate Cancer, Part I

December 12th 2012

Dr. Shore on the Management of Patients with CRPC

December 12th 2012

Dr. Shore Discusses Therapy Combination in CRPC

December 12th 2012

Management of Patients with Advanced Prostate Cancer

December 12th 2012

Dr. Shore Reviews Emerging Therapies in Prostate Cancer

December 12th 2012

Emerging Therapies in Prostate Cancer

December 12th 2012

Treatments for Post-Docetaxel Prostate Cancer, Part II

December 12th 2012

Treatments for Post-Docetaxel Prostate Cancer, Part I

December 12th 2012